Background
Gallbladder cancer is a are but lethal disease, affecting over 115.000 patients worldwide in 2020. Due to the low incidence, little high quality evidence on treatment is available and as such, there is a significant variation of clinical practise worldwide. In this study, we aim to investigate clinical characteristics, treatment outcomes and survival of patients with gallbladder cancer.
Study design
We feel that international collaboration is paramount to create high-quality evidence. Therefore, this cohort study is performed in a multinational setting, including centres spanning across multiple continents.
All patients with gallbladder cancer aged >18 years are eligible for inclusion. After written informed consent is provided, baseline clinical data as well as data on treatment and follow-up will be entered into a secure, online database. Data entry costs +- 20 minutes per patient. No effort is required on the end of the participant as the only data collected will be data gathered during their regular clinical course.
Outcomes
The primary endpoint is an overview of different treatment modalities, type of surgery performed and their correlation to survival. Secundary outcomes include baseline patient data, data on used diagnostic modalities and regional differences in practise patterns and clinical outcomes.
Planning
As of january 2024, 35 centres across the globe have contributed a total of over 1400 inclusions. Data collection and completion is still ongoing. At least one paper is planned to be formalized this year. In addition, all contributers are able to download their own data and use these for personal quality control.
Interested?
If you’re interested in participating, please contact either of our study coordinators, dr. Philip de Reuver (philip.dereuver@radboudumc.nl) or dr. Elise de Savornin Lohman (elise.desavorninlohman@radboudumc.nl)
Gallbladder cancer registry 